Novacyt
S.A.
("Novacyt", the "Company" or
the "Group")
Statement re. Health and Safety Executive
Prosecution
Paris, France, and Eastleigh and
Manchester, UK - 21 January 2025 - Novacyt S.A. (EURONEXT GROWTH:
ALNOV; AIM: NCYT), an international molecular diagnostics company
with a broad portfolio of integrated technologies and services,
announces that, following an investigation by the Health and Safety
Executive ("HSE"), Lab 21 Healthcare Ltd ("Lab 21"), a non-trading
subsidiary of Novacyt, has been charged with health and safety
offences relating to a facility it previously
operated.
The
charges relate to Lab 21's site based at Axminster, Devon and
relate to the use of biological agents at the site. The lease for
the site was taken over by Lab 21 from Omega Diagnostics Ltd
("Omega"), as part of the acquisition by Lab 21 of Omega's
Infectious Diseases business announced on 28 June 2018. The
operations that are subject to the charges no longer form any part
of the Company's ongoing business.
An
initial Magistrates' Court hearing has been set for 18 March
2025.
The
Company will make a further announcement following the outcome of
the case.
Contacts
|
Novacyt SA
|
https://novacyt.com/investors
|
|
Lyn Rees, Chief Executive
Officer
|
Via Walbrook
PR
|
|
Steve Gibson, Chief Financial
Officer
|
|
|
SP Angel Corporate Finance LLP
(Nominated Adviser and Broker)
|
+44 (0)20
3470 0470
|
|
Matthew Johnson / Charlie Bouverat
(Corporate Finance)
Vadim Alexandre / Rob Rees
(Corporate Broking)
|
|
|
|
|
|
Deutsche Numis (Joint
Broker)
|
+44 (0)20
7260 1000
|
|
Freddie Barnfield / Duncan Monteith
/ Michael Palser
|
|
|
|
|
|
Allegra Finance (French Listing Sponsor)
Rémi Durgetto / Yannick
Petit
|
+33 (1) 42 22 10 10
r.durgetto@allegrafinance.com
/ y.petit@allegrafinance.com
|
|
|
|
|
Walbrook PR (Financial PR &
IR)
Paul McManus / Lianne
Applegarth
Phillip Marriage / Alice
Woodings
|
+44 (0)20
7933 8780 or novacyt@walbrookpr.com
+44
(0)7980 541 893 / +44 (0)7584 391 303
+44
(0)7867 984 082 / +44 (0)7407 804 654
|
|
|
|
|
| |
About Novacyt Group (www.novacyt.com)
Novacyt is an international
molecular diagnostics company providing a broad portfolio of
integrated technologies and services, primarily focused on the
delivery of genomic medicine. The
Company develops, manufactures, and
commercialises a range of molecular assays
and instrumentation to deliver workflows and services that enable
seamless end-to-end solutions from sample to result across multiple
sectors including human health, animal health and environmental.
The Company is divided into three
business segments:
|
Clinical
|
Broad portfolio of human clinical
in vitro diagnostic
products, workflows and services focused on three therapeutic
areas:
·
Reproductive Health: NIPT, Cystic Fibrosis and
other rapid aneuploidy tests
·
Precision Medicine: DPYD genotyping
assay
·
Infectious Diseases: Winterplex, multiplex winter
respiratory PCR panel
|
|
Instrumentation
|
Portfolio of next generation size
selection DNA sample preparation platforms and rapid
PCR machines, including:
·
Ranger® Technology: automated DNA sample
preparation and target enrichment technology
·
genesig q16 and q32 real-time quantitative PCR
(qPCR) instruments
|
|
Research Use Only
|
Range of services for the life
sciences industry:
·
Design, manufacture, and supply of
high-performance qPCR assays and workflows for use in human health,
agriculture, veterinary and environmental, to support global health
organisations and the research industry
·
Pharmaceutical research services: whole genome
sequencing (WGS) / whole exome sequencing (WES)
|
Novacyt is headquartered in Le
Vésinet in France with offices in the UK (in Eastleigh and
Manchester), Singapore, the US and Canada and has a commercial
presence in over 65 countries. The Company is listed on the London
Stock Exchange's AIM market ("NCYT") and on the Paris Stock
Exchange Euronext Growth ("ALNOV").
For more information, please refer
to the website: www.novacyt.com
